Heather J Chalfin1, Stephanie A Glavaris2, Paymaneh D Malihi3, Jamie M Sperger4, Michael A Gorin2, Changxue Lu2, C Rory Goodwin5, Yan Chen2, Emily A Caruso2, Ruth Dumpit6, Peter Kuhn3, Joshua M Lang4, Peter S Nelson6, Jun Luo2, Kenneth J Pienta2. 1. The James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland; Department of Urology, Johns Hopkins University School of Medicine, Baltimore, Maryland. Electronic address: heather.chalfin@jhmi.edu. 2. The James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland; Department of Urology, Johns Hopkins University School of Medicine, Baltimore, Maryland. 3. Bridge Institute, University of Southern California, Los Angeles, California. 4. Department of Medicine, University of Wisconsin Carbone Cancer Center, Madison, Wisconsin. 5. Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, Maryland. 6. Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Abstract
PURPOSE: Prostate circulating tumor cells escape into peripheral blood and enter bone marrow as disseminated tumor cells, representing an early step before conventionally detectable metastasis. It is unclear how frequently this occurs in localized disease and existing detection methods rely on epithelial markers with low specificity and sensitivity. We used multiple methodologies of disseminated tumor cell detection in bone marrow harvested at radical prostatectomy. MATERIALS AND METHODS: Bone marrow was harvested from 208 clinically localized cases, 16 controls and 5 metastatic cases with peripheral blood obtained from 37 metastatic cases. Samples were evaluated at 4 centers with 4 distinct platforms using antibody enrichment with the AdnaTest (Qiagen®) or VERSA (versatile exclusion based rare sample analysis), or whole sample interrogation with the RareCyte platform (Seattle, Washington) or HD-SCA (high definition single cell assay) using traditional epithelial markers and prostate specific markers. We investigated the sensitivity and specificity of these markers by evaluating expression levels in control and metastatic cases. RESULTS: EpCAM, NKX3.1 and AR were nonspecifically expressed in controls and in most samples using AdnaTest with no relation to perioperative variables. Only 1 patient with localized disease showed positive results for the prostate specific marker PSA. With the VERSA platform no localized case demonstrated disseminated tumor cells. With the RareCyte and HD-SCA platforms only a single patient had 1 disseminated tumor cell. CONCLUSIONS: Evaluation across multiple platforms revealed that epithelial markers are nonspecific in bone marrow and, thus, not suitable for disseminated tumor cell detection. Using prostate specific markers disseminated tumor cells were typically not detected in patients with localized prostate cancer.
PURPOSE: Prostate circulating tumor cells escape into peripheral blood and enter bone marrow as disseminated tumor cells, representing an early step before conventionally detectable metastasis. It is unclear how frequently this occurs in localized disease and existing detection methods rely on epithelial markers with low specificity and sensitivity. We used multiple methodologies of disseminated tumor cell detection in bone marrow harvested at radical prostatectomy. MATERIALS AND METHODS: Bone marrow was harvested from 208 clinically localized cases, 16 controls and 5 metastatic cases with peripheral blood obtained from 37 metastatic cases. Samples were evaluated at 4 centers with 4 distinct platforms using antibody enrichment with the AdnaTest (Qiagen®) or VERSA (versatile exclusion based rare sample analysis), or whole sample interrogation with the RareCyte platform (Seattle, Washington) or HD-SCA (high definition single cell assay) using traditional epithelial markers and prostate specific markers. We investigated the sensitivity and specificity of these markers by evaluating expression levels in control and metastatic cases. RESULTS:EpCAM, NKX3.1 and AR were nonspecifically expressed in controls and in most samples using AdnaTest with no relation to perioperative variables. Only 1 patient with localized disease showed positive results for the prostate specific marker PSA. With the VERSA platform no localized case demonstrated disseminated tumor cells. With the RareCyte and HD-SCA platforms only a single patient had 1 disseminated tumor cell. CONCLUSIONS: Evaluation across multiple platforms revealed that epithelial markers are nonspecific in bone marrow and, thus, not suitable for disseminated tumor cell detection. Using prostate specific markers disseminated tumor cells were typically not detected in patients with localized prostate cancer.
Authors: Dena Marrinucci; Kelly Bethel; Anand Kolatkar; Madelyn S Luttgen; Michael Malchiodi; Franziska Baehring; Katharina Voigt; Daniel Lazar; Jorge Nieva; Lyudmila Bazhenova; Andrew H Ko; W Michael Korn; Ethan Schram; Michael Coward; Xing Yang; Thomas Metzner; Rachelle Lamy; Meghana Honnatti; Craig Yoshioka; Joshua Kunken; Yelena Petrova; Devin Sok; David Nelson; Peter Kuhn Journal: Phys Biol Date: 2012-02-03 Impact factor: 2.583
Authors: Mathias Uhlén; Linn Fagerberg; Björn M Hallström; Cecilia Lindskog; Per Oksvold; Adil Mardinoglu; Åsa Sivertsson; Caroline Kampf; Evelina Sjöstedt; Anna Asplund; IngMarie Olsson; Karolina Edlund; Emma Lundberg; Sanjay Navani; Cristina Al-Khalili Szigyarto; Jacob Odeberg; Dijana Djureinovic; Jenny Ottosson Takanen; Sophia Hober; Tove Alm; Per-Henrik Edqvist; Holger Berling; Hanna Tegel; Jan Mulder; Johan Rockberg; Peter Nilsson; Jochen M Schwenk; Marica Hamsten; Kalle von Feilitzen; Mattias Forsberg; Lukas Persson; Fredric Johansson; Martin Zwahlen; Gunnar von Heijne; Jens Nielsen; Fredrik Pontén Journal: Science Date: 2015-01-23 Impact factor: 47.728
Authors: Stephen J Freedland; Elizabeth B Humphreys; Leslie A Mangold; Mario Eisenberger; Frederick J Dorey; Patrick C Walsh; Alan W Partin Journal: JAMA Date: 2005-07-27 Impact factor: 56.272
Authors: Daniel F Hayes; Massimo Cristofanilli; G Thomas Budd; Matthew J Ellis; Alison Stopeck; M Craig Miller; Jeri Matera; W Jeffrey Allard; Gerald V Doyle; Leon W W M Terstappen Journal: Clin Cancer Res Date: 2006-07-15 Impact factor: 12.531
Authors: Steven J Cohen; Cornelis J A Punt; Nicholas Iannotti; Bruce H Saidman; Kert D Sabbath; Nashat Y Gabrail; Joel Picus; Michael Morse; Edith Mitchell; M Craig Miller; Gerald V Doyle; Henk Tissing; Leon W M M Terstappen; Neal J Meropol Journal: J Clin Oncol Date: 2008-07-01 Impact factor: 44.544
Authors: Vasudha Murlidhar; Mina Zeinali; Svetlana Grabauskiene; Mostafa Ghannad-Rezaie; Max S Wicha; Diane M Simeone; Nithya Ramnath; Rishindra M Reddy; Sunitha Nagrath Journal: Small Date: 2014-07-29 Impact factor: 13.281
Authors: Gregor Eisenwort; Jennifer Jurkin; Nighat Yasmin; Thomas Bauer; Bernhard Gesslbauer; Herbert Strobl Journal: J Invest Dermatol Date: 2011-06-16 Impact factor: 8.551
Authors: Dan Robinson; Eliezer M Van Allen; Yi-Mi Wu; Nikolaus Schultz; Robert J Lonigro; Juan-Miguel Mosquera; Bruce Montgomery; Mary-Ellen Taplin; Colin C Pritchard; Gerhardt Attard; Himisha Beltran; Wassim Abida; Robert K Bradley; Jake Vinson; Xuhong Cao; Pankaj Vats; Lakshmi P Kunju; Maha Hussain; Felix Y Feng; Scott A Tomlins; Kathleen A Cooney; David C Smith; Christine Brennan; Javed Siddiqui; Rohit Mehra; Yu Chen; Dana E Rathkopf; Michael J Morris; Stephen B Solomon; Jeremy C Durack; Victor E Reuter; Anuradha Gopalan; Jianjiong Gao; Massimo Loda; Rosina T Lis; Michaela Bowden; Stephen P Balk; Glenn Gaviola; Carrie Sougnez; Manaswi Gupta; Evan Y Yu; Elahe A Mostaghel; Heather H Cheng; Hyojeong Mulcahy; Lawrence D True; Stephen R Plymate; Heidi Dvinge; Roberta Ferraldeschi; Penny Flohr; Susana Miranda; Zafeiris Zafeiriou; Nina Tunariu; Joaquin Mateo; Raquel Perez-Lopez; Francesca Demichelis; Brian D Robinson; Marc Schiffman; David M Nanus; Scott T Tagawa; Alexandros Sigaras; Kenneth W Eng; Olivier Elemento; Andrea Sboner; Elisabeth I Heath; Howard I Scher; Kenneth J Pienta; Philip Kantoff; Johann S de Bono; Mark A Rubin; Peter S Nelson; Levi A Garraway; Charles L Sawyers; Arul M Chinnaiyan Journal: Cell Date: 2015-05-21 Impact factor: 41.582
Authors: Johann S de Bono; Howard I Scher; R Bruce Montgomery; Christopher Parker; M Craig Miller; Henk Tissing; Gerald V Doyle; Leon W W M Terstappen; Kenneth J Pienta; Derek Raghavan Journal: Clin Cancer Res Date: 2008-10-01 Impact factor: 12.531
Authors: Frank C Cackowski; Yugang Wang; Joseph T Decker; Christopher Sifuentes; Steven Weindorf; Younghun Jung; Yu Wang; Ann M Decker; Kenji Yumoto; Nicholas Szerlip; Laura Buttitta; Kenneth J Pienta; Todd M Morgan; Russell S Taichman Journal: Prostate Date: 2019-08-26 Impact factor: 4.104
Authors: Sarah R Amend; Amber E de Groot; Gonzalo Torga; Haley D Axelrod; Diane K Reyes; Kenneth C Valkenburg; Stephanie A Glavaris; Kenneth J Pienta Journal: Am J Clin Exp Urol Date: 2018-04-01
Authors: Nan Sethakorn; Erika Heninger; Cristina Sánchez-de-Diego; Adeline B Ding; Ravi Chandra Yada; Sheena C Kerr; David Kosoff; David J Beebe; Joshua M Lang Journal: Cancers (Basel) Date: 2022-02-01 Impact factor: 6.639
Authors: Almudena Zapatero; Antonio Gómez-Caamaño; María Ángeles Cabeza Rodriguez; Laura Muinelo-Romay; Carmen Martin de Vidales; Alicia Abalo; Patricia Calvo Crespo; Luis Leon Mateos; Carlos Olivier; Lorena Vega Vega Piris Journal: Radiat Oncol Date: 2020-06-01 Impact factor: 3.481
Authors: Erika Heninger; Nan Sethakorn; David Kosoff; Peiman Hematti; Morgan D Kuczler; Kenneth J Pienta; Joshua M Lang Journal: Oncotarget Date: 2020-11-17